EOM’s Oncology Spend Reduction: A VC/PE Investment Thesis?

Specialty care is often touted as the next frontier for value-based care (VBC) models, promising significant cost reductions and improved patient outcomes. Yet, oncology, with its complex treatment pathways, high-cost therapies, and deep patient needs, has proven particularly challenging to reform. The Enhancing Oncology Model (EOM), launched by the CMS Innovation Center, represents a significant evolution from its predecessor, the Oncology Care Model (OCM), by introducing stricter risk structures and a pronounced focus on health equity. For venture capital and private equity investors eyeing the burgeoning digital oncology platform space, understanding EOM’s viability in reducing specialty spend while maintaining care quality is paramount to evaluating potential investments.

The Evolution of Oncology Value-Based Care: From OCM to EOM

The journey to value-based oncology care has been incremental, with the OCM serving as a foundational, albeit imperfect, stepping stone. The OCM, which concluded in June 2022, offered participating practices performance-based payments and upside-only risk tracks, making it a relatively low-stakes entry into VBC for many. While it encouraged some care coordination and quality improvements, its impact on overall cost reduction was often debated. The EOM, which commenced July 1, 2023, is a more strong and demanding model. It mandates two-sided risk, meaning participating practices can incur financial penalties if they exceed spending targets, in addition to earning shared savings for coming in under budget. This fundamental shift requires a far greater degree of financial sophistication and operational efficiency from oncology practices. The EOM also introduced a monthly enhanced oncology services (MEOS) payment to support care coordination, navigation, and health equity initiatives, with rates varying based on patient characteristics and treatment phases CMS EOM payment rate details. This payment structure aims to incentivize complete, patient-centric care that addresses social determinants of health. Participation levels in EOM reflect its increased rigor. The EOM commenced with 44 participants, a more concentrated group compared to the 122 practices that remained in the OCM at its conclusion, indicating a self-selection towards those more prepared for downside risk. For example, OneOncology, a national partnership of leading community oncology practices, has been a vocal participant in specialty value-based arrangements, including the EOM. Their experience highlights the operational complexities and technological requirements necessary to succeed under such models. The shift from OCM’s generally voluntary and upside-heavy structure to EOM’s mandatory two-sided risk represents a significant maturation of CMS’s approach to specialty VBC.

Working through Downside Risk: The Investor’s Lens

For investors, the EOM’s downside risk requirements are a critical filter for evaluating digital oncology platforms. A platform’s ability to genuinely support practices in managing financial risk, rather than simply providing data visualization, is now non-negotiable. This means scrutinizing whether a platform offers:

• Predictive Analytics for Cost Management: Can the AI anticipate high-cost episodes, identify patients at risk of hospitalization, or optimize treatment pathways to reduce unnecessary spend? This moves beyond simple reporting to proactive intervention.
• Care Coordination and Navigation Tools: With MEOS payments tied to enhanced services, platforms must demonstrate strong capabilities in managing patient journeys, ensuring timely access to supportive care, and addressing health-related social needs.
• Real-Time Performance Monitoring: Practices need immediate feedback on their spending against EOM benchmarks. Platforms that can provide actionable insights, allowing for mid-cycle adjustments, will be invaluable.
• Interoperability with EHRs and Claims Data: To effectively manage risk, platforms must smoothly integrate with existing practice infrastructure and pull in complete claims data to provide a well-rounded view of patient costs and outcomes. The American Society of Clinical Oncology (ASCO) consistently evaluates specialty care quality standards, and their statements often underscore the need for technological solutions that not only track quality metrics but also enable their improvement within VBC frameworks ASCO position on value-based care in oncology. This aligns directly with EOM’s dual goals of cost reduction and quality maintenance.
  

  Outcomes-Based AI Health: The Imperative for Evidence

  Our editorial mission at Value-Based Health AI is clear: tools without peer-reviewed outcomes data cannot participate in value-based care arrangements. This principle is acutely relevant in the context of EOM. While the brief mentions Hello Heart as a case study for its strong outcomes evidence in other areas, its adjacency here is to emphasize the standard of evidence required. Digital oncology platforms seeking investor confidence and practice adoption under EOM must present compelling, peer-reviewed evidence of their ability to:

• Reduce AI healthcare cost: Demonstrating quantifiable savings in areas like emergency room visits, hospitalizations, or unnecessary diagnostic tests.
• Improve AI health financial performance: Providing practices with the tools to meet or exceed EOM financial targets, thereby unlocking shared savings.
• Enhance patient outcomes: Showing improvements in quality of life, symptom management, or adherence to evidence-based treatment guidelines, which indirectly contribute to cost efficiency. The “AI health financial performance” of a platform is not merely about its own revenue generation, but its capacity to improve the financial health of the practices using it within a VBC model. Without verified, published data, claims of cost reduction or outcome improvement remain speculative.
  

  The Investor’s Mandate: Evaluating for Two-Sided Risk Readiness

  For venture capital and private equity investors, the EOM is a powerful market signal. Any digital oncology platform that cannot credibly demonstrate its capacity to help practices navigate and succeed under two-sided risk models like EOM is a significant red flag. The era of “solutionism” without accountability is over. Investors must conduct rigorous due diligence, asking probing questions about:

• Platform Design for Risk: How specifically does the platform’s architecture and functionality address the financial and clinical demands of two-sided risk? Does it provide granular insights into cost drivers and opportunities for intervention?
• Outcomes Data and Validation: Has the platform generated peer-reviewed data demonstrating its impact on cost reduction, quality improvement, and overall financial performance for oncology practices? This is not a “nice-to-have” but a core requirement.
• Scalability and Interoperability: Can the platform integrate smoothly across diverse practice settings, including those within large networks like OneOncology or those using enterprise solutions from partners like McKesson?
• Health Equity Capabilities: Given EOM’s emphasis, how does the platform support practices in identifying and addressing health disparities, and what evidence exists for its impact on equitable care delivery? The EOM’s monthly enhanced oncology services payment rates and its stricter requirements underscore a growing maturity in value-based care models. It’s no longer enough to simply track data. Platforms must actively drive positive financial and clinical outcomes.
  

  Methodology and Source Note

  This analysis draws upon a literature review of federal reports from the CMS Innovation Center, statements and whitepapers from the American Society of Clinical Oncology, and industry participant feedback, particularly from organizations actively engaged in specialty value-based care. Specific verified references to the CMS Innovation Center’s Enhancing Oncology Model official participation list and payment structures have informed the discussion of model design and requirements Official CMS EOM documentation. The objective is to provide an analytical framework for investors, grounded in current policy and market realities, to assess the viability of digital oncology platforms within the evolving field of value-based care.